Latest research on Guanfacine

A centrally acting antihypertensive agent. The drug lowers both systolic and diastolic blood pressure by activating the central nervous system alpha-2 adrenoreceptors, which results in reduced sympathetic outflow leading to reduced vascular tone. Its adverse reactions include dry mouth, sedation, and constipation. [PubChem]

Latest findings

To date, in Canada, the only medication approved by Health Canada for adjunctive therapy to stimulants in children aged 6–12 years is Intuniv XR™ (Guanfacine extended release [GXR]; Shire Canada Inc., Saint-Laurent, QC, Canada). [source, 2016]
Alpha agonists such as Guanfacine and Clonidine have been found to be useful in the treatment of mild tics and may have a particular benefit in patients with co-existing ADHD and impulse control disorder [source, 2016]
Clonidine and Guanfacine can improve working memory in aged monkeys with documented memory impairment (Arnsten and Goldman-Rakic, 1985, 1987; Arnsten et al., 1988). [source, 2015]
It has also been attempted with a noradrenergic agent, Guanfacine, which improved visual search in neglect patients without frontal damage. [source, 2015]
Data from a pooled sample of children and adolescent patients (n = 2357), aged 6–17 years, with a confirmed Statistical Manual of Mental Disorders version IV text revision (DSM-IV-TR) primary diagnosis of ADHD, who participated in one of seven Phase III randomized, double-blind, placebo-controlled trials of Guanfacine hydrochloride extended-release (GXR; Intuniv, Shire US, Inc., Wayne, Pennsylvania, USA) or Lisdexamfetamine dimesylate (Vyvanse, Shire US, Inc.) [27–33]. [source, 2015]
The effect of α1 agonism contrasted with that of the α2 receptor agonist Guanfacine, which had little effect. [source, 2015]
Published data supporting use of other agents approved by the FDA, including Atomoxetine, Clonidine, and Guanfacine, specifically in persons with FXS, remains limited. [source, 2015]
Early studies testing effects of Guanfacine and Modafinil on DRD are promising. [source, 2015]
One study found that intramuscular Guanfacine reduced DRD in rhesus monkeys (Kim et al., 2012) and a second found dose-dependent reduction in DRD in rats when Guanfacine was administered locally in the ventral hippocampus (Abela and Chudasama, 2014). [source, 2015]
The use of non-stimulants in the treatment of patients with ADHD such as Guanfacine may be effective and reduce the potential abuse or diversion. [source, 2015]